Telephone sharing button Contact Us linkedin sharing button Share wechat sharing button Share wechat sharing button Twitter mailbox sharing button info@wuxibiologics.com
arrow_left sharing button
arrow_right sharing button

Press Releases

WuXi PharmaTech Completes Construction of New Biosafety Testing Facility in Suzhou
May. 13, 2014
WuXi PharmaTech Completes Construction of New Biosafety Testing Facility in Suzhou

SHANGHAI, May 13, 2014 — WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology, and medical device R&D services company with operations in China and the United States, today announced that construction has been completed on a new biologics biosafety testing facility in Suzhou.


The facility consists of 38,000 square feet of laboratories and support areas in a building adjacent to WuXi’s GLP preclinical drug safety facility. Operations will begin after validations are completed this summer. Service offerings will include clinical and commercial lot release programs, viral clearance testing, and virus and molecular-based safety detection services for Chinese and multinational customers.


The new services will expand WuXi’s already broad, integrated platform of biologics services. In the United States, WuXi offers biosafety testing services such as viral clearance validation and lot release and stability testing. In China, the company’s services include novel monoclonal antibody discovery, discovery biology, drug screening, cell-line engineering and construction, toxicology, bioanalytical services, assay development, formulation, process development, and cGMP drug-substance and drug-product manufacturing for clinical trials.


“WuXi’s expanding capabilities help our customers advance their biologic product candidates through development more quickly and cost-effectively,” said Dr. Ge Li, Chairman and CEO of WuXi PharmaTech. “By investing in capabilities that address our customers’ needs, we have become a leading biologics solution provider.”

Notice:

You are leaving WuXi Biologics Website, after which our Privacy Notice will not apply. Please keep it in mind the protection of your privacy. Are you willing to proceed?